OA12.01. Analysis of FDA mandated dietary supplement adverse event reports (AER) 2008-2009
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6882
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
OA12.01. Analysis of FDA mandated dietary supplement adverse event reports (AER) 2008-2009 ; volume:12 ; number:1 ; day:12 ; month:6 ; year:2012 ; pages:1 ; date:6.2012
BMC complementary and alternative medicine ; 12, Heft 1 (12.6.2012), 1, 6.2012
- Urheber
-
Hardy, M.
- Beteiligte Personen und Organisationen
-
Stumpf, S.
Zimmerman, M.
Carr, C.
SpringerLink (Online service)
- DOI
-
10.1186/1472-6882-12-S1-O45
- URN
-
urn:nbn:de:1111-2016072931780
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hardy, M.
- Stumpf, S.
- Zimmerman, M.
- Carr, C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
FDA
FDA
FDA
FDA
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
AER
Aer.
Aer
Aer
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
FDA
FDA
FDA
FDA
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
AER
Aer.
Aer
Aer
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
FDA
FDA
FDA
FDA
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
AER
Aer.
Aer